Dana Investment Advisors Inc. trimmed its holdings in Iqvia Holdings Inc (NYSE:IQV) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,220 shares of the medical research company’s stock after selling 858 shares during the period. Dana Investment Advisors Inc.’s holdings in Iqvia were worth $3,511,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Argent Trust Co increased its stake in shares of Iqvia by 0.5% during the fourth quarter. Argent Trust Co now owns 15,406 shares of the medical research company’s stock worth $1,790,000 after purchasing an additional 80 shares during the period. Utah Retirement Systems increased its stake in shares of Iqvia by 0.3% during the fourth quarter. Utah Retirement Systems now owns 30,360 shares of the medical research company’s stock worth $3,527,000 after purchasing an additional 100 shares during the period. Creative Planning increased its stake in shares of Iqvia by 4.2% during the fourth quarter. Creative Planning now owns 2,925 shares of the medical research company’s stock worth $340,000 after purchasing an additional 118 shares during the period. Ffcm LLC increased its stake in shares of Iqvia by 10.8% during the fourth quarter. Ffcm LLC now owns 1,544 shares of the medical research company’s stock worth $179,000 after purchasing an additional 150 shares during the period. Finally, HL Financial Services LLC increased its stake in shares of Iqvia by 4.8% during the fourth quarter. HL Financial Services LLC now owns 3,654 shares of the medical research company’s stock worth $424,000 after purchasing an additional 167 shares during the period. 89.58% of the stock is owned by institutional investors.

In other Iqvia news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.80, for a total transaction of $569,462,784.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider W Richard Staub sold 27,025 shares of the firm’s stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $140.54, for a total value of $3,798,093.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,075,345 shares of company stock worth $573,760,078. Corporate insiders own 6.00% of the company’s stock.

Iqvia stock opened at $141.53 on Friday. Iqvia Holdings Inc has a one year low of $91.57 and a one year high of $144.77. The company has a debt-to-equity ratio of 1.57, a quick ratio of 1.10 and a current ratio of 1.10. The firm has a market cap of $27.99 billion, a price-to-earnings ratio of 27.64, a P/E/G ratio of 1.70 and a beta of 0.85.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 14th. The medical research company reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.03. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same quarter last year, the company earned $1.40 EPS. The company’s revenue was up 6.6% on a year-over-year basis. Equities research analysts expect that Iqvia Holdings Inc will post 5.87 earnings per share for the current fiscal year.

IQV has been the topic of a number of recent research reports. Piper Jaffray Companies increased their target price on Iqvia to $148.00 and gave the stock a “neutral” rating in a research note on Friday, February 15th. UBS Group set a $170.00 target price on Iqvia and gave the stock a “buy” rating in a research note on Friday, February 15th. Barclays reiterated a “buy” rating and set a $155.00 target price on shares of Iqvia in a research note on Friday, February 15th. Goldman Sachs Group upgraded Iqvia from a “buy” rating to a “conviction-buy” rating in a research note on Friday, January 11th. Finally, Morgan Stanley increased their target price on Iqvia from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, December 3rd. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $146.13.

TRADEMARK VIOLATION NOTICE: “Iqvia Holdings Inc (IQV) Stake Lessened by Dana Investment Advisors Inc.” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2019/03/16/iqvia-holdings-inc-iqv-stake-lessened-by-dana-investment-advisors-inc.html.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.